Showing results (561-570 of 701) with videos related to
Sort By:
Pageof 71
Journal of Molecular Biology|May 5, 2004
Structural studies of the Nudix hydrolase DR1025 from Deinococcus radiodurans and its ligand complexesWasantha Ranatunga, Emma E Hill, Jana L Mooster, et al.Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|May 16, 2001
Colonic mucosal prostaglandin E2 and cyclooxygenase expression before and after low aspirin doses in subjects at high risk or at normal risk for colorectal cancerK Krishnan, M T Ruffin, D Normolle, et al.The Journal of Molecular Diagnostics : JMD|August 17, 2010
Reliable gene expression measurements from fine needle aspirates of pancreatic tumors: effect of amplicon length and quality assessmentMichelle A Anderson, Dean E Brenner, James M Scheiman, et al.Journal of Clinical Immunology|December 25, 2012
Newborn screening for SCID identifies patients with ataxia telangiectasiaJacob Mallott, Antonia Kwan, Joseph Church, et al.Journal of the National Cancer Institute|August 6, 1997
Suppression of human colorectal mucosal prostaglandins: determining the lowest effective aspirin doseM T Ruffin, K Krishnan, C L Rock, et al.Global Change Biology|December 19, 2021
Non-stationary and interactive effects of climate and competition on pink salmon productivityJan Ohlberger, Eric J Ward, Richard E Brenner, et al.JCO Global Oncology|October 3, 2025
Diagnostic Translational Considerations for Global Health Settings: Portable Detection of Human Papillomavirus for Cervical Cancer Screening in IndiaVi T Nguyen, Siril Arockiam, Pankaj Kumar, et al.Frontiers in Immunology|August 18, 2025
Serum profiling of the antibody response to HPV in women with or without abnormal cervical cytology undergoing cervical cancer screeningRadwa Ewaisha, Mack T Ruffin, Stacy Williams, et al.Cancer Chemotherapy and Pharmacology|January 1, 1989
A phase I clinical trial of recombinant human tumor necrosis factor given daily for five daysP J Creaven, D E Brenner, J W Cowens, et al.Cancer|June 1, 1977
Immunosuppression and human cancer: role of prostaglandinsH A Harvey, J C Allegra, L M Demers, et al.Pageof 71